↓ Skip to main content

Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations

Overview of attention for article published in Journal for Immunotherapy of Cancer, January 2018
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#28 of 2,590)
  • High Attention Score compared to outputs of the same age (98th percentile)

Mentioned by

news
12 news outlets
twitter
120 tweeters
patent
5 patents
wikipedia
2 Wikipedia pages

Citations

dimensions_citation
687 Dimensions

Readers on

mendeley
797 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations
Published in
Journal for Immunotherapy of Cancer, January 2018
DOI 10.1186/s40425-018-0316-z
Pubmed ID
Authors

Jun Gong, Alexander Chehrazi-Raffle, Srikanth Reddi, Ravi Salgia

Abstract

Early preclinical evidence provided the rationale for programmed cell death 1 (PD-1) and programmed death ligand 1 (PD-L1) blockade as a potential form of cancer immunotherapy given that activation of the PD-1/PD-L1 axis putatively served as a mechanism for tumor evasion of host tumor antigen-specific T-cell immunity. Early-phase studies investigating several humanized monoclonal IgG4 antibodies targeting PD-1 and PD-L1 in advanced solid tumors paved way for the development of the first PD-1 inhibitors, nivolumab and pembrolizumab, approved by the Food and Drug Administration (FDA) in 2014. The number of FDA-approved agents of this class is rapidly enlarging with indications for treatment spanning across a spectrum of malignancies. The purpose of this review is to highlight the clinical development of PD-1 and PD-L1 inhibitors in cancer therapy to date. In particular, we focus on detailing the registration trials that have led to FDA-approved indications of anti-PD-1 and anti-PD-L1 therapies in cancer. As the number of PD-1/PD-L1 inhibitors continues to grow, predictive biomarkers, mechanisms of resistance, hyperprogressors, treatment duration and treatment beyond progression, immune-related toxicities, and clinical trial design are key concepts in need of further consideration to optimize the anticancer potential of this class of immunotherapy.

Twitter Demographics

The data shown below were collected from the profiles of 120 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 797 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 797 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 129 16%
Student > Ph. D. Student 125 16%
Student > Bachelor 91 11%
Student > Master 85 11%
Other 51 6%
Other 109 14%
Unknown 207 26%
Readers by discipline Count As %
Medicine and Dentistry 157 20%
Biochemistry, Genetics and Molecular Biology 156 20%
Agricultural and Biological Sciences 61 8%
Immunology and Microbiology 57 7%
Pharmacology, Toxicology and Pharmaceutical Science 48 6%
Other 85 11%
Unknown 233 29%

Attention Score in Context

This research output has an Altmetric Attention Score of 156. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 May 2022.
All research outputs
#192,597
of 21,355,489 outputs
Outputs from Journal for Immunotherapy of Cancer
#28
of 2,590 outputs
Outputs of similar age
#5,468
of 399,719 outputs
Outputs of similar age from Journal for Immunotherapy of Cancer
#1
of 1 outputs
Altmetric has tracked 21,355,489 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,590 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 14.3. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 399,719 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 98% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them